Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PHIBRO ANIMAL HEALTH CORPPAHC · Entity 4671 | Chief Operating Officer | August 06, 2026 | September 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PHIBRO ANIMAL HEALTH CORP
Report date August 06, 2026 · Filed September 17, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 38,275 |
Reported balance
After 2026-08-06 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-08-06 · Grant · Acquired 3,726 · Balance 38,275 F1: The reported securities represent restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of Class A Common Stock. F2: The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2026, subject to the Reporting Person's continued employment through the applicable vesting date. F3: This amendment to the Form 4 filed on August 10, 2026 (the "Original Form 4") corrects the number of RSUs granted on August 6, 2026, which was inadvertently understated in the Original Form 4 due to a calculation error. The reported amount in this amendment correctly reflects the number of RSUs granted on August 6, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities represent restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of Class A Common Stock.
F2: The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2026, subject to the Reporting Person's continued employment through the applicable vesting date.
F3: This amendment to the Form 4 filed on August 10, 2026 (the "Original Form 4") corrects the number of RSUs granted on August 6, 2026, which was inadvertently understated in the Original Form 4 due to a calculation error. The reported amount in this amendment correctly reflects the number of RSUs granted on August 6, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 06, 2026 Filed Sep 17, 2026 21:32 UTC Amendment | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | GrantClass A Common Stock | 3,726 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-108617 · tm2625682-1_4aseq1.xml · nonDerivative · entry 1 Miller Larry Lee · CIK 0001603584 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,275 F1 · security: The reported securities represent restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of Class A Common Stock. F2 · shares: The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2026, subject to the Reporting Person's continued employment through the applicable vesting date. F3 · shares: This amendment to the Form 4 filed on August 10, 2026 (the "Original Form 4") corrects the number of RSUs granted on August 6, 2026, which was inadvertently understated in the Original Form 4 due to a calculation error. The reported amount in this amendment correctly reflects the number of RSUs granted on August 6, 2026. Read SEC document |
| August 06, 2026 Filed Aug 10, 2026 20:17 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | GrantClass A Common Stock | 3,522 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-093391 · tm2622592-6_4seq1.xml · nonDerivative · entry 1 Miller Larry Lee · CIK 0001603584 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,071 F1 · security: The reported securities represent restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of Class A Common Stock. F2 · shares: The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2026, subject to the Reporting Person's continued employment through the applicable vesting date. Read SEC document |
| August 04, 2026 Filed Aug 7, 2026 00:11 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | OtherClass A Common Stock | 635 | $36.60 | $23,240.37 |
DisclosureSEC source: 0001104659-26-092230 · tm2622506-4_4seq1.xml · nonDerivative · entry 1 Miller Larry Lee · CIK 0001603584 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,549 F1 · shares: Represents shares sold in a broker assisted cashless exercise program to satisfy tax withholding obligations upon the receipt of Class A Common Stock in connection with the vesting and settlement of restricted stock units. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 20:19 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | GrantClass A Common Stock | 5,184 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-080274 · tm2523826-8_4seq1.xml · nonDerivative · entry 1 Miller Larry Lee · CIK 0001603584 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,184 F1 · security: The reported securities represent restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of Class A Common Stock. F2 · shares: The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2025, subject to the Reporting Person's continued employment through the applicable vesting date. Read SEC document |
| July 05, 2023 Filed Jul 7, 2023 20:16 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | GrantRestricted Stock Units · Derivative | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-079131 · tm2320607-2_4seq1.xml · derivative · entry 1 Miller Larry Lee · CIK 0001603584 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Class A Common Stock · 300,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A Common Stock. F2 · shares: On July 5, 2023, the Compensation Committee approved the grant to the reporting person of 300,000 RSUs subject to performance-based vesting based solely on the Company's stock price. F3 · derivative.exercise_date: The RSUs will vest on June 30, 2027, in increments of 10% (but no less than 20%) (with linear interpolation to apply for achievement between increments) based upon achievement of the arithmetic average of the Company's closing stock price per share for each trading day in the 90 calendar day period ended June 30, 2027 (the "90-Day Average") from $20 to $60 and above, subject to the reporting person's continued employment on such date, and subject to earlier vesting upon certain qualifying termination events. None of the RSUs will vest if the 90-Day Average is below $20, and the maximum vesting percentage for the RSUs is 100% for achievement of a 90-Day Average of $60 or above. Vested shares will be delivered to the reporting person within 30 days after vesting, subject to later delivery in the event of certain trading blackout periods. F3 · derivative.expiration_date: The RSUs will vest on June 30, 2027, in increments of 10% (but no less than 20%) (with linear interpolation to apply for achievement between increments) based upon achievement of the arithmetic average of the Company's closing stock price per share for each trading day in the 90 calendar day period ended June 30, 2027 (the "90-Day Average") from $20 to $60 and above, subject to the reporting person's continued employment on such date, and subject to earlier vesting upon certain qualifying termination events. None of the RSUs will vest if the 90-Day Average is below $20, and the maximum vesting percentage for the RSUs is 100% for achievement of a 90-Day Average of $60 or above. Vested shares will be delivered to the reporting person within 30 days after vesting, subject to later delivery in the event of certain trading blackout periods. F2 · derivative.underlying_shares: On July 5, 2023, the Compensation Committee approved the grant to the reporting person of 300,000 RSUs subject to performance-based vesting based solely on the Company's stock price. F2 · balance_after: On July 5, 2023, the Compensation Committee approved the grant to the reporting person of 300,000 RSUs subject to performance-based vesting based solely on the Company's stock price. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 01:01 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 20,000 | $22.94 | $458,812.00 |
DisclosureSEC source: 0001104659-21-020033 · tm216079d1_4seq1.xml · nonDerivative · entry 2 Miller Larry Lee · CIK 0001603584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs listed in Table II. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.59 to $23.20, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 08, 2021 Filed Feb 11, 2021 01:01 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionRestricted Stock Units · Derivative | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-020033 · tm216079d1_4seq1.xml · derivative · entry 3 Miller Larry Lee · CIK 0001603584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 250,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares were issued in settlement of restricted stock units ("RSUs"). Each RSU represented a contingent right to receive one share of Class A Common Stock. F4 · derivative.exercise_date: RSUs were granted on May 7, 2018, 50,000 RSUs vested on December 31, 2020 and 200,000 performance-based RSUs were cancelled for not meeting the performance requirement. Vested shares were delivered on February 8, 2021. F4 · derivative.expiration_date: RSUs were granted on May 7, 2018, 50,000 RSUs vested on December 31, 2020 and 200,000 performance-based RSUs were cancelled for not meeting the performance requirement. Vested shares were delivered on February 8, 2021. Read SEC document |
| February 08, 2021 Filed Feb 11, 2021 01:01 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionClass A Common Stock | 50,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-020033 · tm216079d1_4seq1.xml · nonDerivative · entry 1 Miller Larry Lee · CIK 0001603584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares were issued in settlement of restricted stock units ("RSUs"). Each RSU represented a contingent right to receive one share of Class A Common Stock. Read SEC document |
| May 07, 2018 Filed May 7, 2018 22:00 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | GrantRestricted Stock Units · Derivative | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-025786 · tv493282_4.xml · derivative · entry 1 Miller Larry Lee · CIK 0001603584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Class A Common Stock · 250,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A Common Stock. F2 · shares: On May 7, 2018, the Compensation Committee approved the grant to the reporting person of 50,000 RSUs subject to time-based vesting and 200,000 RSUs subject to performance-based vesting based solely on the Company's stock price. F3 · derivative.exercise_date: The time-based RSUs will vest on December 31, 2020, and the performance-based RSUs will vest on December 31, 2020 in increments from 0% to 100% based on the 90-day average of the Company's stock price from $0 to $80 ending on December 31, 2020, in each case so long as the reporting person's employment has not been terminated prior to such date, and in each case subject to earlier vesting upon certain qualifying termination events. Vested shares will be delivered to the reporting person 30 days after vesting, subject to later delivery in the event of certain trading blackout periods. F3 · derivative.expiration_date: The time-based RSUs will vest on December 31, 2020, and the performance-based RSUs will vest on December 31, 2020 in increments from 0% to 100% based on the 90-day average of the Company's stock price from $0 to $80 ending on December 31, 2020, in each case so long as the reporting person's employment has not been terminated prior to such date, and in each case subject to earlier vesting upon certain qualifying termination events. Vested shares will be delivered to the reporting person 30 days after vesting, subject to later delivery in the event of certain trading blackout periods. F2 · derivative.underlying_shares: On May 7, 2018, the Compensation Committee approved the grant to the reporting person of 50,000 RSUs subject to time-based vesting and 200,000 RSUs subject to performance-based vesting based solely on the Company's stock price. F2 · balance_after: On May 7, 2018, the Compensation Committee approved the grant to the reporting person of 50,000 RSUs subject to time-based vesting and 200,000 RSUs subject to performance-based vesting based solely on the Company's stock price. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 02:14 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionOption to purchase Common Stock · Derivative | 17,928 | $0.00 Strike: $11.83 | $0.00 |
DisclosureSEC source: 0001144204-18-009411 · tv486260_4.xml · derivative · entry 3 Miller Larry Lee · CIK 0001603584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 17,928 shares Expires 2019-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 4, 2017. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 02:14 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 17,928 | $35.19 | $630,886.32 |
DisclosureSEC source: 0001144204-18-009411 · tv486260_4.xml · nonDerivative · entry 2 Miller Larry Lee · CIK 0001603584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 4, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.73 to $35.60, inclusive. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 02:14 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionClass A Common Stock | 17,928 | $11.83 | $212,088.24 |
DisclosureSEC source: 0001144204-18-009411 · tv486260_4.xml · nonDerivative · entry 1 Miller Larry Lee · CIK 0001603584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,928 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 4, 2017. Read SEC document |
| February 13, 2018 Filed Feb 14, 2018 02:14 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionOption to purchase Common Stock · Derivative | 22,086 | $0.00 Strike: $11.83 | $0.00 |
DisclosureSEC source: 0001144204-18-008232 · tv485591_4.xml · derivative · entry 13 Miller Larry Lee · CIK 0001603584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,928 Underlying: Class A Common Stock · 22,086 shares Expires 2019-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 4, 2017. Read SEC document |
| February 13, 2018 Filed Feb 14, 2018 02:14 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 22,086 | $35.05 | $774,114.30 |
DisclosureSEC source: 0001144204-18-008232 · tv485591_4.xml · nonDerivative · entry 10 Miller Larry Lee · CIK 0001603584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 4, 2017. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.75 to $35.40, inclusive. Read SEC document |
| February 13, 2018 Filed Feb 14, 2018 02:14 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionClass A Common Stock | 22,086 | $11.83 | $261,277.38 |
DisclosureSEC source: 0001144204-18-008232 · tv485591_4.xml · nonDerivative · entry 9 Miller Larry Lee · CIK 0001603584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,086 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 4, 2017. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 02:14 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionOption to purchase Common Stock · Derivative | 18,304 | $0.00 Strike: $11.83 | $0.00 |
DisclosureSEC source: 0001144204-18-008232 · tv485591_4.xml · derivative · entry 12 Miller Larry Lee · CIK 0001603584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,014 Underlying: Class A Common Stock · 18,304 shares Expires 2019-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 4, 2017. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 02:14 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 500 | $36.22 | $18,110.00 |
DisclosureSEC source: 0001144204-18-008232 · tv485591_4.xml · nonDerivative · entry 8 Miller Larry Lee · CIK 0001603584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 4, 2017. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.18 to $36.40, inclusive. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 02:14 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionClass A Common Stock | 500 | $11.83 | $5,915.00 |
DisclosureSEC source: 0001144204-18-008232 · tv485591_4.xml · nonDerivative · entry 7 Miller Larry Lee · CIK 0001603584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 4, 2017. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 02:14 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 17,804 | $35.61 | $634,000.44 |
DisclosureSEC source: 0001144204-18-008232 · tv485591_4.xml · nonDerivative · entry 6 Miller Larry Lee · CIK 0001603584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 4, 2017. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.15 to $36.00, inclusive. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 02:14 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionClass A Common Stock | 17,804 | $11.83 | $210,621.32 |
DisclosureSEC source: 0001144204-18-008232 · tv485591_4.xml · nonDerivative · entry 5 Miller Larry Lee · CIK 0001603584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,804 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 4, 2017. Read SEC document |
| February 09, 2018 Filed Feb 14, 2018 02:14 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionOption to purchase Common Stock · Derivative | 14,182 | $0.00 Strike: $11.83 | $0.00 |
DisclosureSEC source: 0001144204-18-008232 · tv485591_4.xml · derivative · entry 11 Miller Larry Lee · CIK 0001603584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,318 Underlying: Class A Common Stock · 14,182 shares Expires 2019-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 4, 2017. Read SEC document |
| February 09, 2018 Filed Feb 14, 2018 02:14 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 5,600 | $35.69 | $199,864.00 |
DisclosureSEC source: 0001144204-18-008232 · tv485591_4.xml · nonDerivative · entry 4 Miller Larry Lee · CIK 0001603584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 4, 2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.65 to $35.90, inclusive. Read SEC document |
| February 09, 2018 Filed Feb 14, 2018 02:14 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionClass A Common Stock | 5,600 | $11.83 | $66,248.00 |
DisclosureSEC source: 0001144204-18-008232 · tv485591_4.xml · nonDerivative · entry 3 Miller Larry Lee · CIK 0001603584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 4, 2017. Read SEC document |
| February 09, 2018 Filed Feb 14, 2018 02:14 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 8,582 | $35.36 | $303,459.52 |
DisclosureSEC source: 0001144204-18-008232 · tv485591_4.xml · nonDerivative · entry 2 Miller Larry Lee · CIK 0001603584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 4, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.65 to $35.60, inclusive. Read SEC document |
| February 09, 2018 Filed Feb 14, 2018 02:14 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionClass A Common Stock | 8,582 | $11.83 | $101,525.06 |
DisclosureSEC source: 0001144204-18-008232 · tv485591_4.xml · nonDerivative · entry 1 Miller Larry Lee · CIK 0001603584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,582 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 4, 2017. Read SEC document |
| September 14, 2017 Filed Sep 16, 2017 00:09 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionOption to purchase Common Stock · Derivative | 5,548 | $0.00 Strike: $11.83 | $0.00 |
DisclosureSEC source: 0001144204-17-048333 · v475283_form4.xml · derivative · entry 6 Miller Larry Lee · CIK 0001603584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,500 Underlying: Class A Common Stock · 5,548 shares Expires 2019-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2016. Read SEC document |
| September 14, 2017 Filed Sep 16, 2017 00:09 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 5,548 | $36.34 | $201,614.32 |
DisclosureSEC source: 0001144204-17-048333 · v475283_form4.xml · nonDerivative · entry 4 Miller Larry Lee · CIK 0001603584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2016. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.20 to $36.53, inclusive. Read SEC document |
| September 14, 2017 Filed Sep 16, 2017 00:09 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionClass A Common Stock | 5,548 | $11.83 | $65,632.84 |
DisclosureSEC source: 0001144204-17-048333 · v475283_form4.xml · nonDerivative · entry 3 Miller Larry Lee · CIK 0001603584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,548 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2016. Read SEC document |
| September 13, 2017 Filed Sep 16, 2017 00:09 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionOption to purchase Common Stock · Derivative | 15,891 | $0.00 Strike: $11.83 | $0.00 |
DisclosureSEC source: 0001144204-17-048333 · v475283_form4.xml · derivative · entry 5 Miller Larry Lee · CIK 0001603584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,048 Underlying: Class A Common Stock · 15,891 shares Expires 2019-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2016. Read SEC document |
| September 13, 2017 Filed Sep 16, 2017 00:09 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 15,891 | $36.46 | $579,385.86 |
DisclosureSEC source: 0001144204-17-048333 · v475283_form4.xml · nonDerivative · entry 2 Miller Larry Lee · CIK 0001603584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2016. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.30 to $36.60, inclusive. Read SEC document |
| September 13, 2017 Filed Sep 16, 2017 00:09 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionClass A Common Stock | 15,891 | $11.83 | $187,990.53 |
DisclosureSEC source: 0001144204-17-048333 · v475283_form4.xml · nonDerivative · entry 1 Miller Larry Lee · CIK 0001603584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,891 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2016. Read SEC document |
| September 12, 2017 Filed Sep 13, 2017 01:39 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionOption to purchase Common Stock · Derivative | 21,472 | $0.00 Strike: $11.83 | $0.00 |
DisclosureSEC source: 0001144204-17-047743 · v475013_form4.xml · derivative · entry 9 Miller Larry Lee · CIK 0001603584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,939 Underlying: Class A Common Stock · 21,472 shares Expires 2019-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2016. F5 · derivative.exercise_date: The date exercisable for the securities included on this line was previously incorrectly reported. The information in this column reflects the correct date exercisable for Mr. Miller's options to purchase Class A Common Stock. Read SEC document |
| September 12, 2017 Filed Sep 13, 2017 01:39 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 21,472 | $36.45 | $782,654.40 |
DisclosureSEC source: 0001144204-17-047743 · v475013_form4.xml · nonDerivative · entry 6 Miller Larry Lee · CIK 0001603584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2016. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.20 to $36.65, inclusive. Read SEC document |
| September 12, 2017 Filed Sep 13, 2017 01:39 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionClass A Common Stock | 21,472 | $11.83 | $254,013.76 |
DisclosureSEC source: 0001144204-17-047743 · v475013_form4.xml · nonDerivative · entry 5 Miller Larry Lee · CIK 0001603584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,472 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2016. Read SEC document |
| September 11, 2017 Filed Sep 13, 2017 01:39 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionOption to purchase Common Stock · Derivative | 9,700 | $0.00 Strike: $11.83 | $0.00 |
DisclosureSEC source: 0001144204-17-047743 · v475013_form4.xml · derivative · entry 8 Miller Larry Lee · CIK 0001603584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,411 Underlying: Class A Common Stock · 9,700 shares Expires 2019-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2016. F5 · derivative.exercise_date: The date exercisable for the securities included on this line was previously incorrectly reported. The information in this column reflects the correct date exercisable for Mr. Miller's options to purchase Class A Common Stock. Read SEC document |
| September 11, 2017 Filed Sep 13, 2017 01:39 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 9,700 | $36.26 | $351,722.00 |
DisclosureSEC source: 0001144204-17-047743 · v475013_form4.xml · nonDerivative · entry 4 Miller Larry Lee · CIK 0001603584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2016. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.20 to $36.40, inclusive. Read SEC document |
| September 11, 2017 Filed Sep 13, 2017 01:39 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionClass A Common Stock | 9,700 | $11.83 | $114,751.00 |
DisclosureSEC source: 0001144204-17-047743 · v475013_form4.xml · nonDerivative · entry 3 Miller Larry Lee · CIK 0001603584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2016. Read SEC document |
| September 08, 2017 Filed Sep 13, 2017 01:39 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionOption to purchase Common Stock · Derivative | 14,930 | $0.00 Strike: $11.83 | $0.00 |
DisclosureSEC source: 0001144204-17-047743 · v475013_form4.xml · derivative · entry 7 Miller Larry Lee · CIK 0001603584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,111 Underlying: Class A Common Stock · 14,930 shares Expires 2019-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2016. F5 · derivative.exercise_date: The date exercisable for the securities included on this line was previously incorrectly reported. The information in this column reflects the correct date exercisable for Mr. Miller's options to purchase Class A Common Stock. Read SEC document |
| September 08, 2017 Filed Sep 13, 2017 01:39 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 14,930 | $36.19 | $540,316.70 |
DisclosureSEC source: 0001144204-17-047743 · v475013_form4.xml · nonDerivative · entry 2 Miller Larry Lee · CIK 0001603584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2016. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.65, inclusive. Read SEC document |
| September 08, 2017 Filed Sep 13, 2017 01:39 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionClass A Common Stock | 14,930 | $11.83 | $176,621.90 |
DisclosureSEC source: 0001144204-17-047743 · v475013_form4.xml · nonDerivative · entry 1 Miller Larry Lee · CIK 0001603584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,930 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2016. Read SEC document |
| September 07, 2017 Filed Sep 8, 2017 01:13 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionOption to purchase Common Stock · Derivative | 18,825 | $0.00 Strike: $11.83 | $0.00 |
DisclosureSEC source: 0001144204-17-047126 · v474773_4.xml · derivative · entry 13 Miller Larry Lee · CIK 0001603584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,041 Underlying: Class A Common Stock · 18,825 shares Expires 2019-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2016. Read SEC document |
| September 07, 2017 Filed Sep 8, 2017 01:13 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 10,589 | $35.96 | $380,780.44 |
DisclosureSEC source: 0001144204-17-047126 · v474773_4.xml · nonDerivative · entry 10 Miller Larry Lee · CIK 0001603584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2016. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.90 to $36.10, inclusive. Read SEC document |
| September 07, 2017 Filed Sep 8, 2017 01:13 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionClass A Common Stock | 10,589 | $11.83 | $125,267.87 |
DisclosureSEC source: 0001144204-17-047126 · v474773_4.xml · nonDerivative · entry 9 Miller Larry Lee · CIK 0001603584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,589 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2016. Read SEC document |
| September 07, 2017 Filed Sep 8, 2017 01:13 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 8,236 | $35.68 | $293,860.48 |
DisclosureSEC source: 0001144204-17-047126 · v474773_4.xml · nonDerivative · entry 8 Miller Larry Lee · CIK 0001603584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2016. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.90 to $35.88, inclusive. Read SEC document |
| September 07, 2017 Filed Sep 8, 2017 01:13 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionClass A Common Stock | 8,236 | $11.83 | $97,431.88 |
DisclosureSEC source: 0001144204-17-047126 · v474773_4.xml · nonDerivative · entry 7 Miller Larry Lee · CIK 0001603584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,236 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2016. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 01:13 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionOption to purchase Common Stock · Derivative | 8,587 | $0.00 Strike: $11.83 | $0.00 |
DisclosureSEC source: 0001144204-17-047126 · v474773_4.xml · derivative · entry 12 Miller Larry Lee · CIK 0001603584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,866 Underlying: Class A Common Stock · 8,587 shares Expires 2019-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2016. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 01:13 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 8,587 | $34.97 | $300,287.39 |
DisclosureSEC source: 0001144204-17-047126 · v474773_4.xml · nonDerivative · entry 6 Miller Larry Lee · CIK 0001603584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2016. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.70 to $35.20, inclusive. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 01:13 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionClass A Common Stock | 8,587 | $11.83 | $101,584.21 |
DisclosureSEC source: 0001144204-17-047126 · v474773_4.xml · nonDerivative · entry 5 Miller Larry Lee · CIK 0001603584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,587 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2016. Read SEC document |
| September 05, 2017 Filed Sep 8, 2017 01:13 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionOption to purchase Common Stock · Derivative | 5,047 | $0.00 Strike: $11.83 | $0.00 |
DisclosureSEC source: 0001144204-17-047126 · v474773_4.xml · derivative · entry 11 Miller Larry Lee · CIK 0001603584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,453 Underlying: Class A Common Stock · 5,047 shares Expires 2019-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2016. Read SEC document |
| September 05, 2017 Filed Sep 8, 2017 01:13 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 810 | $36.49 | $29,556.90 |
DisclosureSEC source: 0001144204-17-047126 · v474773_4.xml · nonDerivative · entry 4 Miller Larry Lee · CIK 0001603584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2016. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.35 to $36.65, inclusive. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.